TY - JOUR
T1 - Urinary C-type natriuretic peptide
T2 - An emerging biomarker for heart failure and renal remodeling
AU - Zakeri, Rosita
AU - Burnett, John C.
AU - Sangaralingham, S. Jeson
N1 - Funding Information:
This work was supported by a Scientist Development Grant from the American Heart Association ( 13SDG16910051 to Dr. Sangaralingham), grants from the National Institutes of Health ( R01 HL036634 , P01 HL076611 and R01 HL083231 to Dr. Burnett), a Career Development Award in Cardiovascular Research — St. Jude Foundation (to Dr. Sangaralingham) and the Mayo Foundation . This work was also supported by the Mayo Clinic Center for Clinical and Translational Science ( TL1 TR000137 and TL1RR02415 from the National Center for Advancing Translational Sciences [NCATS]; Drs. Sangaralingham and Zakeri). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.
PY - 2015/3/1
Y1 - 2015/3/1
N2 - The public health and economic burden of heart failure (HF) is staggering and the need for relevant pathophysiologic and clinical biomarkers to advance the field and improve HF therapy remains high. Renal dysfunction is common among HF patients and is associated with increased HF hospitalization and mortality. It is widely recognized that mechanisms contributing to HF pathogenesis include a complex bidirectional interaction between the kidney and heart, encompassed by the term cardiorenal syndrome (CRS). Among a new wave of urinary biomarkers germane to CRS, C-type natriuretic peptide (CNP) has emerged as an innovative biomarker of renal structural and functional impairment in HF and chronic renal disease states. CNP is a hormone, synthesized in the kidney, and is an important regulator of cell proliferation and organ fibrosis. Hypoxia, cytokines and fibrotic growth factors, which are inherent to both cardiac and renal remodeling processes, are among the recognized stimuli for CNP production and release. In this review we aim to highlight current knowledge regarding the biology and pathophysiological correlates of urinary CNP, and its potential clinical utility as a diagnostic and prognostic biomarker in HF and renal disease states.
AB - The public health and economic burden of heart failure (HF) is staggering and the need for relevant pathophysiologic and clinical biomarkers to advance the field and improve HF therapy remains high. Renal dysfunction is common among HF patients and is associated with increased HF hospitalization and mortality. It is widely recognized that mechanisms contributing to HF pathogenesis include a complex bidirectional interaction between the kidney and heart, encompassed by the term cardiorenal syndrome (CRS). Among a new wave of urinary biomarkers germane to CRS, C-type natriuretic peptide (CNP) has emerged as an innovative biomarker of renal structural and functional impairment in HF and chronic renal disease states. CNP is a hormone, synthesized in the kidney, and is an important regulator of cell proliferation and organ fibrosis. Hypoxia, cytokines and fibrotic growth factors, which are inherent to both cardiac and renal remodeling processes, are among the recognized stimuli for CNP production and release. In this review we aim to highlight current knowledge regarding the biology and pathophysiological correlates of urinary CNP, and its potential clinical utility as a diagnostic and prognostic biomarker in HF and renal disease states.
KW - Biomarker
KW - C-type natriuretic peptide
KW - Cardiorenal syndrome
KW - Heart failure
KW - Renal remodeling
UR - http://www.scopus.com/inward/record.url?scp=84924260095&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84924260095&partnerID=8YFLogxK
U2 - 10.1016/j.cca.2014.12.009
DO - 10.1016/j.cca.2014.12.009
M3 - Review article
C2 - 25512164
AN - SCOPUS:84924260095
VL - 443
SP - 108
EP - 113
JO - Clinica Chimica Acta
JF - Clinica Chimica Acta
SN - 0009-8981
ER -